ReviewPostepy dermatologii i alergologii2023
The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications.
Review in Postepy dermatologii i alergologii, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Antimicrobial Peptides of the Skin: Roles in Skin Cancer and Clinical Applications.Experimental dermatology · 2026Review
- Article
- The Latest Advances in Rosacea Treatment: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Molecular networking-based GC/MS profiling of Citrus japonica Thunb. peel and pulp lipophilic fractions and their antimicrobial potential against diabetic foot ulcer pathogens.Scientific reports · 2026Article
- Deep subsurface rock-hosted chemolithotrophic bacterial communities exhibited differential COScientific reports · 2026Article
- Azelaic acid-integrated therapeutic deep eutectic systems: overcoming solubility and permeability barriers for enhanced transdermal drug delivery.RSC advances · 2026Article
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds.Health science reports · 2026Article
- Azelaic acid alleviates UVB-induced photoaging in keratinocytes by restoring Smad-dependent TGF-β signaling.Frontiers in medicine · 2026Article
- Targeting macrophage polarization: mechanisms and potential of mesenchymal stromal/stem cells therapy in acne treatment- a narrative review.Frontiers in immunology · 2026Review
- Effects of Combined Bacterial Infection and Radiation Injury on Biofluid Metabolite Profiles in the Murine Model.ACS omega · 2025Article
- Integration of localized microbiome, metabolome, and clinical datasets predicts healing in chronic wounds among veterans.bioRxiv : the preprint server for biology · 2025Article
- Review
- An open-label pilot study on an adsorbent mousse containing adelmidrol in client-owned cats with feline atopic skin syndrome and associated seborrhoea.Veterinary dermatology · 2025Article
- A Comprehensive Review of Azelaic Acid Pharmacological Properties, Clinical Applications, and Innovative Topical Formulations.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Repurposing the Antibiotic D-Cycloserine for the Treatment of Hyperpigmentation: Therapeutic Potential and Mechanistic Insights.International journal of molecular sciences · 2025Article
- A preliminary study of serum metabolomic profiling in male patients with acute brucellosis.Scientific reports · 2025Article
- Harnessing Azelaic Acid for Acute Myeloid Leukemia Treatment: A Novel Approach to Overcoming Chemoresistance and Improving Outcomes.International journal of molecular sciences · 2025Review
- In Vitro and In Vivo Assessment of an Innovative Peeling System with Azelaic and Tranexamic Acids for Targeted Hyperpigmentation Reduction.Dermatology and therapy · 2025Article
- Usage Frequency and Ecotoxicity of Skin Depigmenting Agents.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Medicinal effects of Ephedra foeminea aqueous extracts: Metabolomic characterization, biological evaluation, and molecular docking.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Azelaic acid (AZA) is a naturally occurring saturated dicarboxylic acid whose topical application has found multiple uses in dermatology. Its anti-inflammatory, antioxidant and antimicrobial properties against Propionibacterium acne are currently used in the treatment of various types of acne such as rosacea and acne vulgaris. AZA is an inhibitor of tyrosinase, mitochondrial respiratory chain enzymes and DNA synthesis, and is a scavenger of harmful free radicals and inhibits the production of reactive oxygen species by neutrophils. Interestingly, AZA also has anti-proliferative and cytotoxic effects on various cancer cells. To date, its inhibitory effect on melanocytes has been mainly used, making it widely used in the treatment of hyperpigmentation disorders such as melasma and post-inflammatory hyperpigmentation. Commercially available topical formulations with cosmetic and drug status contain 5% to 20% AZA in the form of gels and creams. The use of liposomal technology allows greater control over the pharmacokinetics and pharmacodynamics of the formulations. When applied topically, AZA is well tolerated, and side effects are limited to generally mild and transient local skin irritation. Importantly, liposomal technology has enabled the drug to penetrate all layers of the skin while maintaining a very high accumulation of the active ingredient. This solution could be revolutionary for the treatment of skin cancer, where until now the main obstacle was poor absorption through the skin, making the treatment require multiple applications to maintain long-term activity levels. In this review, we will present the mechanism of action and pharmacokinetics of AZA. We will summarize its use in the treatment of dermatoses and its potential in skin cancer therapy. We will provide an overview of the preparations available on the market, taking into consideration technologies used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.